Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents

被引：14

作者：

Freitas, Claudia ^{[1
,2
]}

Jacob, Maria ^{[1
]}

Tavares, Nuno ^{[3
]}

Cruz-Martins, Natalia ^{[1
,2
,4
,5
]}

Souto-Moura, Conceicao ^{[6
]}

Araujo, David ^{[1
,2
]}

Novais-Bastos, Helder ^{[1
,2
,4
]}

Santos, Vanessa ^{[1
]}

Fernandes, Gabriela ^{[1
,2
]}

Magalhaes, Adriana ^{[1
]}

Hespanhol, Venceslau ^{[1
,2
]}

Queiroga, Henrique ^{[1
,2
]}

机构：

[1] Ctr Hosp & Univ Sao Joao, Dept Pulmonol, Porto, Portugal

[2] Univ Porto, Fac Med, Dept Med, Alameda Prof Hernani Monteiro, Porto, Portugal

[3] Ctr Hosp & Univ Sao Joao, Dept Oncol, Porto, Portugal

[4] Univ Porto, Inst Res & Innovat Hlth, Metab Nutr & Endocrinol, Rua Alfredo Allen, Porto, Portugal

[5] Univ Porto, Fac Psychol & Educ Sci, Lab Neuropsychophysiol, Porto, Portugal

[6] Ctr Hosp & Univ Sao Joao, Dept Pathol, Porto, Portugal

来源：

ANTI-CANCER DRUGS | 2021年 / 32卷 / 05期

关键词：

anti-PD1; agents; immune checkpoint inhibitors; immunotherapy; modified Glasgow Prognostic Score; nonsmall cell lung carcinoma; TO-LYMPHOCYTE RATIO; C-REACTIVE PROTEIN; SYSTEMIC INFLAMMATORY RESPONSE; ADVERSE EVENTS; CANCER PATIENTS; CHECKPOINT INHIBITORS; NEUTROPHIL-LYMPHOCYTE; RADIATION-THERAPY; SERUM-ALBUMIN; MGPS PREDICTS;

D O I：

10.1097/CAD.0000000000001060

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified Glasgow Prognostic Score (mGPS) and neutrophil-to-lymphocyte ratio (NLR) was assessed. From 77 patients included, 83.2% received at least one prior systemic therapy. Immune-related adverse events (irAE) occurred in 20 patients. A lower mGPS was associated with higher median overall survival (OS), and a lower Eastern Cooperative Oncology Group (ECOG), irAE and fewer metastatic sites with better survival. A trend towards greater OS and progression-free survival (PFS) was stated among patients with NLR 2 with worse OS and irAE with better survival. Pretreatment mGPS seems to be useful for predicting survival among advanced NSCLC patients treated with anti-programmed cell death 1 drugs, with ECOG performance status, irAE occurrence, and number of metastatic sites acting as survival predictors.

引用

页码：567 / 574

页数：8

共 69 条

[1] TUMOR VOLUME IS A PROGNOSTIC FACTOR IN NON-SMALL-CELL LUNG CANCER TREATED WITH CHEMORADIOTHERAPY [J].

Alexander, Brian M. ;

Othus, Megan ;

Caglar, Hale B. ;

Allen, Aaron M. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (05) :1381-1387

[2] Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience [J].

Areses Manrique, Ma Carmen ;

Mosquera Martinez, Joaquin ;

Garcia Gonzalez, Jorge ;

Afonso Afonso, Francisco Javier ;

Lazaro Quintela, Martin ;

Fernandez Nunez, Natalia ;

Azpitarte Raposeiras, Cristina ;

Amenedo Gancedo, Margarita ;

Santome Couto, Lucia ;

Garcia Campelo, Ma Rosario ;

Munoz Iglesias, Jose ;

Cortegoso Mosquera, Alexandra ;

Vilchez Simo, Rocio ;

Casal Rubio, Joaquin ;

Campos Balea, Begona ;

Carou Frieiro, Iria ;

Alonso-Jaudenes Curbera, Guillermo ;

Anido Herranz, Urbano ;

Garcia Mata, Jesus ;

Firvida Perez, Jose Luis .

TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (03) :404-415

[3] Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study [J].

Arrieta, Oscar ;

Michel Ortega, Rosa M. ;

Villanueva-Rodriguez, Geraldine ;

Serna-Thome, Maria G. ;

Flores-Estrada, Diana ;

Diaz-Romero, Consuelo ;

Rodriguez, Cindy M. ;

Martinez, Luis ;

Sanchez-Lara, Karla .

BMC CANCER, 2010, 10

[4] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].

Bagley, Stephen J. ;

Kothari, Shawn ;

Aggarwal, Charu ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Evans, Tracey L. ;

Kosteva, John A. ;

Ciunci, Christine A. ;

Gabriel, Peter E. ;

Thompson, Jeffrey C. ;

Stonehouse-Lee, Susan ;

Sherry, Victoria E. ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

DiLullo, Gloria ;

Cohen, Roger B. ;

Vachani, Anil ;

Langer, Corey J. .

LUNG CANCER, 2017, 106 :1-7

[5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[6] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[7]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[8] Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer [J].

Cannon, Nathan A. ;

Meyer, Jeffrey ;

Iyengar, Puneeth ;

Ahn, Chul ;

Westover, Kenneth D. ;

Choy, Hak ;

Timmerman, Robert .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) :280-285

[9] Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability [J].

Colotta, Francesco ;

Allavena, Paola ;

Sica, Antonio ;

Garlanda, Cecilia ;

Mantovani, Alberto .

CARCINOGENESIS, 2009, 30 (07) :1073-1081

[10] Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients [J].

Cortellini, Alessio ;

Chiari, Rita ;

Ricciuti, Biagio ;

Metro, Giulio ;

Perrone, Fabiana ;

Tiseo, Marcello ;

Bersanelli, Melissa ;

Bordi, Paola ;

Santini, Daniele ;

Giusti, Raffaele ;

Grassadonia, Antonino ;

Di Marino, Pietro ;

Tinari, Nicola ;

De Tursi, Michele ;

Zoratto, Federica ;

Veltri, Enzo ;

Malorgio, Francesco ;

Garufi, Carlo ;

Russano, Marco ;

Anesi, Cecilia ;

Zeppola, Tea ;

Filetti, Marco ;

Marchetti, Paolo ;

Berardi, Rossana ;

Rinaldi, Silvia ;

Tudini, Marianna ;

Silva, Rosa Rita ;

Pireddu, Annagrazia ;

Atzori, Francesco ;

Iacono, Daniela ;

Migliorino, Maria Rita ;

Porzio, Gampiero ;

Cannita, Katia ;

Ficorella, Corrado ;

Buti, Sebastiano .

CLINICAL LUNG CANCER, 2019, 20 (04) :237-+

← 1 2 3 4 5 6 7 →